在血液透析患者的Polatuzumab vedotin药理动力学与扩散大B细胞淋巴瘤
Hajime Yasuda1, Naoko Kaga2, Hikari Taka2
1Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongou, Bunkyo-Ku, Tokyo, 113-8421, Japan. hyasuda@juntendo.ac.jp.
Cancer chemotherapy and pharmacology
|September 26, 2023
概括
波拉图祖马布维多丁 (PV) 在血液透析 (HD) 患有扩散性大B细胞淋巴瘤 (DLBCL) 的患者中与非HD患者相比显示出类似的药理动力学. 这表明PV对于患有HD的DLBCL患者来说是一种潜在的安全和可行的治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 血液透析 (HD) 患者的化疗需要仔细调整剂量和时间,因为药物的药理动力学发生了变化.
- 针对CD79b的抗体-药物结合体Polatuzumab vedotin (PV) 对扩散型大B细胞淋巴瘤 (DLBCL) 显示出前景.
- 在HD患者中,PV的药理动力学在很大程度上仍未被描述.
研究的目的:
- 为了研究波拉图祖马布维多丁 (PV) 的药理动力学,在进行血液透析 (HD) 的扩散性大B细胞淋巴瘤 (DLBCL) 患者中.
- 为了比较HD和非HD患者之间的PV药理动力学.
- 评估PV在HD患者中的临床可行性和安全性.
主要方法:
- 对DLBCL患者进行了药理动力学研究,在HD期间接受1.2mg/kg的PV.
- PV与达穆斯丁和修复药同时使用.
- 分析了抗体结合和未结合MMAE的血清度,并与非HD患者的历史数据进行了比较.
主要成果:
- 抗体结合和未结合的MMAE的血清度-时间概况在HD患者和非HD患者之间是可比的.
- 血液透析表明,对抗体结合的和未结合的MMAE的消除有限.
- 在HD患者中,用1.2mg/kg的PV给药在临床上是可行的,没有观察到外围神经病变.
结论:
- 波拉图祖马布维多丁 (PV) 在血液透析的DLBCL患者中表现出可预测的药理动力学.
- 在HD期间有限的药物消除表明标准剂量可能是合适的.
- 对需要血液透析的DLBCL患者来说,PV疗法似乎是一种安全和可行的治疗选择.
相关概念视频
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
154
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
154
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61
Renal Drug Excretion: Tubular Secretion
210
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
210
Drug Distribution: Tissue Binding
2.7K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.7K
Drug Elimination by Renal Route: Tubular Secretion
2.4K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.4K
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
258
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
258


